Multiple Myeloma
Analyzing Ide-cel’s Trade-offs of Efficacy and Toxicity in Myeloma
During a live event, Patrick Moore, MD, discussed the superior efficacy with ide-cel vs standard care in relapsed/refractory multiple myeloma.
Read More
Cancer Research Across Continents: Fujiwara’s Path From Japan to the US
In this episode of Emerging Experts, Yu Fujiwara, MD, shares his journey from Japan to the United States and his path to becoming a specialist in hematology and oncology.
Listen
Oncologists Favor CAR T-Cell Therapy for Early Relapsed Myeloma
Oncologists are increasingly favoring CAR T-cell therapy’s early-line use in relapsed/refractory multiple myeloma despite challenges like cost and access.
Dhakal Reflects on the FDA Approval of Cilta-Cel for Earlier Lines of RRMM
In this episode of Targeted Talks, Binod Dhakal, MD, MS, discusses the recent FDA approval of ciltacabtagene autoleucel for the treatment of relapsed/refractory multiple myeloma.
Velcheti Evaluates Activity of Repotrectinib for ROS1 Fusion–Positive NSCLC
During a Case-Based Roundtable® event, Vamsidhar Velcheti, MD, discussed the TRIDENT-1 trial and practical considerations for repotrectinib in non–small cell lung cancer.
Orlowski Discusses Treatment Path Through Successive Relapses of Multiple Myeloma
During a Case-Based Roundtable® event, Robert Z. Orlowski, MD, PhD, discussed the case of a patient who had progression of multiple myeloma after quadruplet frontline with transplant.
